Prevalence of HIV/AIDS among Breast Cancer Patients and the associated Clinico-pathological features
Sseggwanyi J1, Galukande M1, Fualal J2, Jombwe J2 Affi liations:1-Department of Surgery, Makerere University College of Health Sciences, Kampala 2-Department of Surgery, Mulago National Referral Hospital, Kampala Correspondence author: Moses Galukande, Department of Surgery, College of Health Sciences Makerere University P.O. Box 7072 Kampala, Uganda E-mail:
Introduction: There is uncertainty as to the exact interaction between HIV and Breast Cancer. Available studies are inconclusive about any relation whether causal or protective and the number of patients in these studies small.
Objective: To determine the prevalence of HIV among confirmed incident breast cancer cases and to describe the associated clinico-pathological features.
Design: Analytical cross sectional study
Methods: Over a period of 6 months consecutively eligible patients were recruited from the Mulago Hospital breast clinic. Breast lesions were biopsied and blood withdrawn for HIV sero-survey. Collected data was double entered into Epidata version v 3.1.1, exported to STATA 10.0 for analysis.
Results: Sixty two breast cancer patients consented to participate in the study and of these, 22(35.48%) were positive for HIV compared to HIV prevalence in the general population of 6-7%. All the participants were female. The mean age of HIV negative subjects was 45 years (range: 21-80 years) and for HIV positive subjects was 32.4 years (range 18-52 years). There was a significant association between HIV status and age, BMI and CD4 Counts as well as for histological grade and stage (P< 0.024).
Conclusion: The prevalence of HIV among the studied breast cancer group was significantly higher than that in the general population. HIV was associated with poor prognostic factors. A high index of suspicion of the co-existence of these two diseases in a context of high HIV preva-lence is warranted. Future studies should explore for a causal association.
Global statistics demonstrate that almost one third (32%) of all cancers diagnosed in women are breast can-cer (1). In Uganda, the incidence of breast cancer has risen from 11:100,000 in the 1960s to 31:100,000 in 2006 (2). It is second to Kaposi sarcoma in cancers affecting women in the HIV/AIDS (3). The breast tumors seen in Sub Sa-haran Africa present in relatively younger women and mostly in late stage (III and IV), run an aggressive course and carry a low 5 year survival rate (56%) (4, 5) .
Sub-Saharan Africa still remains the region most heav-ily affected by HIV worldwide, accounting for over two thirds (67%) of all people living with HIV and for nearly three quarters (72%) of AIDS-related deaths in 2008. An estimated 1.9 million [1.6 million–2.2 million] people were newly infected with HIV in sub-Saharan Africa in 2008, bringing to 22.4 million [20.8 million–24.1 mil-lion] the number of people living with HIV (6). Non-AIDS-defining cancers that have shown increased incidence in studies of population-based registries of people with HIV/AIDS include multiple myeloma, lip cancer and lung cancer , but data about Breast cancer as an AIDS or Non AIDS defining cancer is limited and con-flicting (8) and the association of HIV infection with breast carcinoma is still unclear (9). The longer patient survival of HIV patients is expected to result in higher prevalence of breast cancer in these patients (10).
Patients with HIV and breast cancer present two distinct challenges to the clinician: to confirm the diagnosis and accurately stage breast cancer, and to evaluate the safety and timing of surgery and adjuvant treatment in the set-ting of immunosuppression (11, 12). There is no clear data about the clinicopathological cor-relation of breast cancer in HIV-positive patients and their current prevalence is not known in our setting.
This study was conducted to determine the prevalence of HIV in breast Ca patients and determine if the clinico-pathological features of the disease are different in HIV+ versus HIV- patients
Study Design: An analytical cross sectional study Study Duration: The study was conducted over a period of six months from January 2011 to June 2011 inclusive. Study Setting: Mulago hospital is the National Referral and Teaching hospital for Makerere University in central Uganda. It has a bed capacity of about 1700. Incident cases were recorded from Mulago hospital surgical out-patient department (breast clinic) and ward 3C (in-pa-tient ward).
All patients with histologically confirmed breast cancer who were able to give relevant information and consent to participate in the study were included.
The sample size (n) was calculated using the modified simple random sampling formula by Wayne , seek-ing to establish the prevalence of subjects. Ethical ap-proval was sought and all participants consented.
HIV diagnosis was made using a standard diagnostic method. The blood was tested once using the ELISA method which is 99.3% to 99.7% sensitive and 99.7% specific (Statpak test kit) . The participants under-went pre and post HIV/AIDS screening counseling by a trained counselor.
Core breast biopsies, fixed in 10% formalin solution were processed for paraffin embedding for Heamatoxy-lin and Eosin staining at the Pathology Department of Mulago Hospital. The slides were reported according to Evans Histological classification and Nottingham grad-ing of tumors (19).
Data Collection and Analysis
Data were entered, verified and analyzed using the Epi-data and SPSS computer program. The confidence inter-val was set at 95%. The level of significance as p<0.05.
A total of 62 participants with histological diagnoses of breast cancer were studied. Of these, 22 participants were positive for HIV (35.5%). There was a significant relationship between HIV status and the socio-demo-graphic plus clinic pathological characteristics except tribe among the 62 Breast cancer participants (Table 1).
The study findings demonstrated a 35.5% prevalence of HIV among this group of patients with breast can-cer. This is similar to a study done 10 years earlier at the same facility that found the HIV prevalence to be 35.7% (16). Given that the HIV prevalence in the general popu-lation is 6.7% (17), a 7-fold difference in prevalence in this breast cancer patients group may suggest a link be-tween breast cancer and HIV infection even though this study wasn’t designed to confirm a causal relationship.
We would have anticipated a corresponding drop in prevalence of HIV among breast cancer patients since HIV in the general population has dropped over the years among the age group that tested positive (18).
Our findings demonstrate a mean age of 32.4 years among the HIV positives. This finding also suggests that breast cancer is affecting the younger population compared to earlier studies which found the mean age for breast cancer to be 41.7years and 47 years (4, 5, 13). While breast cancer seems to be more common in age group of 30-39years, participants that had both HIV and breast cancer were mostly observed among the 18-29years group. The predominance among pre meno-pausal women begs the question whether HIV infection may indeed be a risk factor.
BMI, CD4 count and stage
The proportions of subjects with normal Body Mass In-dex (BMI) were almost equally distributed by HIV sta-tus. However high BMI was most observed among the non-reactive (83.87%). Perhaps the comorbid condi-tions that come with HIV infection are likely to have reduced the patient weights. Among the 22 reactive par-ticipants, 8 (36%) were on treatment with anti-retroviral drugs (ART). Among those who never had ART (64%), 3 (21.4%) were only prophylactic treatment as recom-mended by Ministry of Health (MoH) guidelines which state that; Cotrimoxazole prophylaxis should be given to all HIV-infected adults and children in Uganda regard-less of whether they are on antiretroviral therapy (ART) or not. The low use of prophylaxis may be explained ei-ther by the delay in HIV diagnosis or limited access to care. These subjects were however referred to HIV care centres for the prophylaxis and further treatment. Among the HIV positives, 3(13.6%) had their CD4 less than 250cells/mm3. Nineteen (86.4%) respondents and all those who were HIV negative had their CD4+ counts greater than 250cell/mm3